Medicare chief: ‘Door is really open’ on coverage for new Alzheimer’s drug

 

Medicare is willing to reevaluate its coverage of Alzheimer’s drugs in light of a new therapy, called lecanemab, that has shown potentially more promising patient data than its controversial predecessor, Aduhelm, according to the official who oversees the program.

https://www.statnews.com/2022/12/08/medicare-chief-door-is-really-open-on-coverage-for-new-alzheimers-drug/